Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 420 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
How did BBNX's recent EPS compare to expectations?
The most recent EPS for Beta Bionics Inc is $, expectations of $.
How did Beta Bionics Inc BBNX's revenue perform in the last quarter?
Beta Bionics Inc revenue for the last quarter is $
What is the revenue estimate for Beta Bionics Inc?
According to of Wall street analyst, the revenue estimate of Beta Bionics Inc range from $ to $
What's the earning quality score for Beta Bionics Inc?
Beta Bionics Inc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Beta Bionics Inc report earnings?
Beta Bionics Inc next earnings report is expected in
What are Beta Bionics Inc's expected earnings?
Beta Bionics Inc expected earnings is $, according to wall-street analysts.
Did Beta Bionics Inc beat earnings expectations?
Beta Bionics Inc recent earnings of $ expectations.